Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
AMES, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Matthew L. Sherman, M.D. to the Company's Board of Directors.  In connection with this appointment, the Company's Board will be comprised of eight directors.
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , April 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences: Deutsche Bank 43 rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston   Bank of America Merrill Lynch
View HTML
Toggle Summary NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
AMES, Iowa , April 25, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Society of Clinical Oncology ( ASCO ) 2018 Annual Meeting in Chicago.
View HTML
Toggle Summary NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
AMES, Iowa , April 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its first quarter 2018 financial results on Thursday, May 3 , 2018.  The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
View HTML
Toggle Summary NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
AMES, Iowa --(BUSINESS WIRE)--Apr. 17, 2018-- NewLink Genetics Corporation (NASDAQ:NLNK) today presented a poster entitled “Indoximod modulates AhR-driven transcription of genes that control immune function ” in the Immunomodulatory Agents and Interventions session at the American Association for
View HTML
Toggle Summary NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary
Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition AMES, Iowa , April 15, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported initial data from NLG2105 , a Phase 1 study evaluating indoximod, its IDO pathway
View HTML
Toggle Summary NewLink Genetics Announces Review of Clinical Programs
AMES, Iowa , April 06, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced a review of its clinical programs.    This morning’s announcement by Incyte and Merck on the ECHO-301 trial for patients with advanced melanoma is a disappointing result for the IDO field. 
View HTML
Toggle Summary NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference
AMES, Iowa , April 03, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today it will present at the H. C. Wainwright Annual Global Life Sciences Conference .  The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco .
View HTML
Toggle Summary NewLink Genetics Appoints Chad A. Johnson to Board of Directors
AMES, Iowa, March 21, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Chad A. Johnson, 39, to the Company's Board of Directors.  In connection with this appointment, the Company's Board expanded from seven directors to eight.
View HTML
Toggle Summary NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
AMES, Iowa , March 14, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago.
View HTML